Preferences of Belgorod primary care phycisians in the treatment of a new coronavirus infection


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. COVID-19 is a disease with rapidly increasing morbidity and mortality, resulting in a significant increase in the workload placed on healthcare. In order to achieve high quality care for patients with this infection, it is necessary to apply modern approaches to the treatment of COVID-19. Objective. Assessment of the preferences of Belgorod doctors in choosing treatment regimens for a new coronavirus infection and their compliance with official recommendations. Methods. In this study, 156 clinical cases of treatment of patients with suspected or confirmed novel coronavirus infection were analyzed. All clinical cases were divided into two groups: patients who received therapy before confirmation of COVID-19, or with a negative PCR test (group «COVID-19 (-)»), and patients who received therapy after confirmation of COVID-19 (group « COVID-19 (+)"). The following groups of drugs were analyzed: «Antiviral drugs», «Immunomodulatory drugs», «Antibacterial drugs», «Anticoagulants and antiaggregants», «Mucolitics and antitussive drugs», «Vitamins», «Glucocorticosteroids», «Other drugs». Results. In the COVID-19 (-) grouP., antivirals (89%) and the “Other drugs" (69.5%) were most frequently prescribed. Immunomodulatory drugs (58.5%), vitamins (50%), mucolytics and antitussive drugs (41.5%), as well as antibacterial agents (34.1%) were prescribed less frequently. The proportion of anticoagulants and antiplatelet agents accounted for only 7.3% of prescriptions. In the COVID-19 (+) grouP., immunomodulating agents (88.4%) and vitamins (78.3%) were prescribed much more frequently. Antivirals were prescribed as often as in the COVID-19 (-) group (89.9%), the role of the “Other drugs" grup decreased to 47.8%, and the group of mucolytics and antitussives - to 23.2%. Antibacterial agents were prescribed in 31.9% of cases, glucocorticosteroids - in 14.5%, and anticoagulants and antiaggregants - in 13%. Conclusion. According to the analysis of study results, we concluded that at the time of the survey, primary care physicians did not have a sufficiently clear idea of the current rational approaches to the treatment of a new coronavirus infection.

Full Text

Restricted Access

About the authors

Roman A. Bontsevich

Belgorod State National Research University; Medical Center «Azbuka Zdorovya»

Email: dr.bontsevich@gmail.com
Cand. Sci. (Med.), Associate Professor, Department of Pharmacology and Clinical Pharmacology; General Practitioner, Pulmonologist, Clinical Pharmacologist Belgorod, Russia; Belgorod, Russia

Ya. R Vovk

Kursk State Medical University; LLC «MedLine»

Kursk, Russia; Belgorod, Russia

V. A Vinyukov

Belgorod State National Research University

Belgorod, Russia

D. G Dubonosova

Belgorod State National Research University; City polyclinic

Belgorod, Russia

References

  1. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 15 (22.02.2022).
  2. Asselah T., Durantel D., Pasmant E., et al. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021;74(1):168-184. doi: 10.1016/j.jhep.2020.09.031.
  3. Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-60. doi: 10.23750/abm.v91i1.9397.
  4. COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020;288(2):192-206. doi: 10.1111/joim.13091.
  5. Majumder J., Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. doi: 10.1208/s12248-020-00532-2.
  6. Bontsevich R., Vinyukov V., Subina T., et al. The frequency of prescribing antimicrobial drugs in the initial therapy of COVID-19 at the outpatient stage. Eur Respir J.2021;58(suppl 65):PA3675. doi: 10.1183/13993003.congress-2021.PA3675.
  7. Yu L.M., Bafadhel M., Dorward J., et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10303):743-755.
  8. Agusti A., Torres F., Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respir Med. 2021;9(7):672-73. doi: 10.1016/S2213-2688(21)88171-5.
  9. Yu L.-M., Bafadhel M., Dorward J., et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. Medrxiv. 2021. Published online April 12.
  10. Bontsevich R., Vovk Y., Solovyova L. Practical experience in optimizing Covid-19 therapy in an outpatient setting. Eur Respir J. Sep 2021;57(suppl 65):PA3677. doi: 18.1183/13993883.congress-2021.PA3677.
  11. Бонцевич Р.А. Разработка и внедрение программы поддержки врачебных решений в амбулаторной практике работы с КОВИД19-инфекцией. Сборник трудов научно-практической конференции «Актуальные вопросы лекарственного обеспечения и контроль качества препаратов». Воронеж, 2021. С. 121.
  12. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 6 (28.04.2020).
  13. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7 (03.06.2020).
  14. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 9 (26.10.2022).

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies